Generic Drug Approved for Relapsing Multiple Sclerosis

Today, Novartis announced the FDA granted approval to glatiramer acetate injection (Glatopa) 40-mg/mL for the treatment of multiple sclerosis (MS). Novartis also announced the launch of the generic drug, according to a company press release.
Glatiramer acetate injection received approval as a fully-substitutable, AP-rated generic of Copaxone 40-mg/mL, indicated as a 3-times per week treatment for relapsing forms of MS, according to the release.
The 40-mg/mL and 20-mg/mL formulations of glatiramer acetate will offer patients multiple dosing options to best meet their needs, according to the release.
Glatiramer acetate 20-mg/mL was previously launched in June 2015 and Novartis said that patients can expect the same services for the 40-mg/mL formulation.
Under Sandoz GlatopaCare, patients may qualify to avoid a co-payment, in addition to personalized injection training. The program also offers 24-hour access to nurses for medication questions and a free starter kit that includes the Glatopaject device used for both prefilled syringe doses, according to the release.
Common adverse events with glatiramer acetate injection 20mg/mL include injection site reactions and chest pain. Common adverse events with the 40mg/mL formulation were injection site reactions, Novartis reported.
"The approval and launch of Glatopa 40 mg/mL reinforces our leadership in delivering complex, differentiated generic products,” said Richard Francis, CEO, Sandoz. “We look forward to bringing this product to patients and healthcare professionals and providing a full range of patient support services for Glatopa through GlatopaCare.”

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 

Most Popular

Related Articles

An HIV primary care program is working to reduce the number of new HIV diagnoses and increase viral suppression rates in Long Island and Queens.
Fingolimod (Gilenya, Novartis) is the first FDA-approved treatment to treat multiple sclerosis in pediatric patients.
ALS is a progressive disease in which the motor neurons eventually die, and mortality is usually the result of respiratory failure. Currently, there is no cure for ALS. However, in the last decade advances have been made in both discovery and research that are promising. As new therapies enter the forefront of ALS care, a multitude of healthcare professionals will need to understand more about the disease state, therapy, and their role within ALS care. This activity will explain the impact of amyotrophic lateral sclerosis (ALS) and the value of early diagnosis; examine recent ALS therapy advances, including the efficacy and mechanism of action of new agents; analyze the implications of ALS therapy in the managed care setting; and distinguish the need for integrations among physicians and specialty and managed care pharmacists in the coordination of care for patients with ALS.
Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.